tradmap

DXCM Financials DexCom

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has grown 19.3% per year over the past 5 years.
  • Net income has grown slower than revenue (8.8% vs 19.3% per year).
  • Operating margin has expanded, at 19.6% in the latest year.
  • Free cash flow has grown 31.2% per year over the past 5 years.

Financial health

  • Total debt has grown slower than revenue (-18.9% vs 19.3% per year).
  • Operating income covered interest expense 50× in the latest year.
Revenue & net income
-$127M $2B $5B $0 2011 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
-18% 25% 69% 0% 2011 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Return on equity & assets (ROE / ROA)
-51% -8% 35% 0% 2011 2013 2015 2017 2019 2021 2023 2025
ROEROA
Free cash flow (CFO − capex)
-$43M $517M $1B $0 2011 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $569M $1B 2011 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$2B -$123M $1B $0 2011 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MROEROAFCFTotal debtCash
2025 $4.7B $836M 60.1% 19.6% 30.5% 13.2% $1.1B — $918M
2024 $4.0B $576M 60.5% 14.9% 27.4% 8.9% $631M — $606M
2023 $3.6B $542M 63.2% 16.5% 26.2% 8.6% $512M — $566M
2022 $2.9B $341M 64.7% 13.4% 16.0% 6.3% $305M — $642M
2021 $2.4B $217M 68.6% 10.9% 10.6% 4.4% $53M — $1.1B
2020 $1.9B $550M 66.4% 15.5% 35.4% 12.8% $277M — $818M
2019 $1.5B $101M 63.1% 9.6% 11.5% 4.2% $135M — $446M
2018 $1.0B -$127M 64.4% -18.1% -19.2% -6.6% $56M — $1.1B
2017 $719M -$50M 68.5% -5.9% — -5.6% $26M — $442M
2016 $573M -$66M 66.0% -11.1% — -16.3% $500000 — $95M
2015 — -$58M — — — -19.7% $16M — $86M
2014 — -$22M — — — -12.1% $7M $5M $72M
2013 — -$30M — — — -24.3% -$6M $7M $43M
2012 — -$55M — — — -51.4% -$43M $7M $8M
2011 — -$45M — — — -37.1% -$38M — $3M

Valuation over time

How the market has priced DXCM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 70.3 140.5 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/E
Price / sales (P/S)
0.0 8.2 16.5 Mar '23 Sep '23 Mar '24 Sep '24 Mar '25 Sep '25 Mar '26 Sep '26
P/S

Frequently asked questions

Is DXCM growing its revenue and profit?

Over the past 5 years, DexCom's revenue has grown 19.3% per year, and net income grown 8.8% per year. These are computed facts, not advice.

How much debt does DXCM have?

As of FY2025, DexCom reported — of total debt against $918M of cash; operating income covered interest expense 50×.

What is DXCM's profit margin?

In FY2025, gross margin was 60.1%, operating margin 19.6%, and net margin 17.9%.

What is DXCM's P/E ratio?

DexCom's P/E (TTM) is 31.90 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the DXCM stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 37.8× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.